Spots Global Cancer Trial Database for non small cell lung cancer metastatic
Every month we try and update this database with for non small cell lung cancer metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis | NCT03363685 | Spinal Metastas... Non-Small-Cell ... | 18 Years - 75 Years | Ruijin Hospital | ||
| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | NCT04471415 | Advanced Solid ... Non Small Cell ... | DRP-104 atezolizumab | 18 Years - | Dracen Pharmaceuticals, Inc. | |
| Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | NCT04233021 | Non Small Cell ... Leptomeningeal ... Brain Metastase... EGFR Activating... | Osimertinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | NCT05117242 | Non Small Cell ... | Acasunlimab Pembrolizumab | 18 Years - | Genmab | |
| PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | NCT03774732 | Non Small Cell ... Non Small Cell ... Non-Small Cell ... | Radiotherapy Pembrolizumab Chemotherapy | 18 Years - | UNICANCER | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) | NCT04621188 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer | NCT01658813 | Gastrointestina... Renal Cell Canc... Non Small Cell ... | 5-Fluorouracil ... | 18 Years - | Western Regional Medical Center | |
| Thyroid Dysfunction and Nivolumab Reponse in NSCLC | NCT04470440 | Non Small Cell ... Treatment Adver... Thyroid Dysfunc... Immune Checkpoi... Prognosis | 18 Years - | University Hospital, Brest | ||
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | NCT03846310 | Non Small Cell ... Non Small Cell ... Nonsquamous Non... Sensitizing EGF... | Etrumadenant Zimberelimab Carboplatin Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| Cancer Panel From Blood of Lung Cancer Patients | NCT03235765 | Non Small Cell ... Non Small Cell ... | MACROGEN Pan Ca... | 20 Years - | Seoul National University Hospital | |
| Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer | NCT03035890 | Non Small Cell ... | Radiation Immuno-Therapeu... | 18 Years - | West Virginia University | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma | NCT04951583 | Non Small Cell ... Advanced Melano... | FMT + ICI | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | NCT03533127 | Non Small Cell ... Non Small Cell ... Non Small Cell ... | LY01008 Bevacizumab | 18 Years - 75 Years | Luye Pharma Group Ltd. | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) | NCT03715985 | Malignant Melan... Non Small Cell ... Bladder Urothel... | EVAX-01-CAF09b | 18 Years - 120 Years | Herlev Hospital | |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | NCT03319628 | Platinum Resist... Non Small Cell ... | upifitamab rils... | 18 Years - | Mersana Therapeutics | |
| Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer | NCT05864794 | Non Small Cell ... | MRI | 18 Years - | University Medical Center Groningen | |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | NCT03319628 | Platinum Resist... Non Small Cell ... | upifitamab rils... | 18 Years - | Mersana Therapeutics | |
| Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | NCT04471415 | Advanced Solid ... Non Small Cell ... | DRP-104 atezolizumab | 18 Years - | Dracen Pharmaceuticals, Inc. | |
| JDQ443 for KRAS G12C NSCLC Brain Metastases | NCT05999357 | Non Small Cell ... Brain Metastase... KRAS G12C | JDQ443 | 18 Years - | Maastricht University Medical Center | |
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | NCT03353675 | Non Small Cell ... | TG4010 Chemotherapy Nivolumab | 18 Years - | Transgene | |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | NCT02978404 | Clear-Cell Meta... Non Small Cell ... Brain Metastase... Small Cell Lung... Melanoma | Nivolumab Radiosurgery | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib | NCT06378892 | Non Small Cell ... ALK Gene Mutati... | Lorlatinib | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients | NCT03334071 | Non Small Cell ... Non Small Cell ... Non Small Cell ... | Exercise | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | NCT03907852 | Mesothelioma Mesothelioma, M... Mesothelioma; P... Mesotheliomas P... Mesothelioma Pe... Cholangiocarcin... Cholangiocarcin... Ovarian Cancer Non Small Cell ... Non Small Cell ... High Grade Ovar... | gavo-cel fludarabine cyclophosphamid... Nivolumab Ipilimumab | 18 Years - | TCR2 Therapeutics | |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | NCT02978404 | Clear-Cell Meta... Non Small Cell ... Brain Metastase... Small Cell Lung... Melanoma | Nivolumab Radiosurgery | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer | NCT03035890 | Non Small Cell ... | Radiation Immuno-Therapeu... | 18 Years - | West Virginia University | |
| 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer | NCT01658813 | Gastrointestina... Renal Cell Canc... Non Small Cell ... | 5-Fluorouracil ... | 18 Years - | Western Regional Medical Center | |
| Thyroid Dysfunction and Nivolumab Reponse in NSCLC | NCT04470440 | Non Small Cell ... Treatment Adver... Thyroid Dysfunc... Immune Checkpoi... Prognosis | 18 Years - | University Hospital, Brest | ||
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | NCT03977194 | Non Small Cell ... | Carboplatin Paclitaxel Atezolizumab | 70 Years - 89 Years | Intergroupe Francophone de Cancerologie Thoracique | |
| Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | NCT03377023 | Non Small Cell ... Lung Cancer, No... Non Small Cell ... | Nivolumab Ipilimumab Nintedanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | NCT05599789 | Non Small Cell ... | Pembrolizumab i... | 18 Years - | Peking Union Medical College Hospital | |
| Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients | NCT03334071 | Non Small Cell ... Non Small Cell ... Non Small Cell ... | Exercise | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases | NCT03732482 | Non Small Cell ... | Temozolomide ca... radiotherapy | 18 Years - 80 Years | Taizhou Hospital | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Her2-positive Lung Cancer Treated With Dedicated Drug | NCT03845270 | Non Small Cell ... Non Small Cell ... HER2 Gene Mutat... | pertuzumab + tr... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Liquid Biopsy Based NGS in Newly Diagnosed NSCLC | NCT05853887 | Non Small Cell ... Newly Diagnosed... Non-Squamous No... | iNUDGE | - | Abramson Cancer Center at Penn Medicine | |
| Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer | NCT04111705 | Non Small Cell ... | Lorlatinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | NCT03307785 | Neoplasms Metastatic Canc... Advanced Cancer Solid Tumor Non Small Cell ... Non Small Cell ... Non Small Cell ... | Niraparib TSR-042 Carboplatin-Pac... Bevacizumab TSR-022 Carboplatin-Pem... Carboplatin-Nab... | 18 Years - | Tesaro, Inc. | |
| Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | NCT05117242 | Non Small Cell ... | Acasunlimab Pembrolizumab | 18 Years - | Genmab | |
| Liquid Biopsy Based NGS in Newly Diagnosed NSCLC | NCT05853887 | Non Small Cell ... Newly Diagnosed... Non-Squamous No... | iNUDGE | - | Abramson Cancer Center at Penn Medicine | |
| Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | NCT04069936 | Non Small Cell ... Lung Cancer Lung Cancer Met... Lung Cancer, No... Non Small Cell ... NSCLC Non-small Cell ... Non-small Cell ... | MILs™ - NSCLC nivolumab tadalafil | 18 Years - | WindMIL Therapeutics | |
| Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | NCT02978404 | Clear-Cell Meta... Non Small Cell ... Brain Metastase... Small Cell Lung... Melanoma | Nivolumab Radiosurgery | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05657873 | Non Small Cell ... Non Small Cell ... Non-small Cell ... NSCLC NSCLC Stage IV | L-SABR Anti-PD-(L)1 ba... Platinum based ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | NCT05599789 | Non Small Cell ... | Pembrolizumab i... | 18 Years - | Peking Union Medical College Hospital | |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | NCT03307785 | Neoplasms Metastatic Canc... Advanced Cancer Solid Tumor Non Small Cell ... Non Small Cell ... Non Small Cell ... | Niraparib TSR-042 Carboplatin-Pac... Bevacizumab TSR-022 Carboplatin-Pem... Carboplatin-Nab... | 18 Years - | Tesaro, Inc. | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
